Omron and Medtronic Celebrate First Anniversary of Strategic Collaboration and Expand Partnership into Hypertension Management at CIIE 2023

Nov 07, 2023 21:06 CST Updated 21:06

Medtronic

Medical Device Manufacturer

NEWS TODAY

Omron and Medtronic

Strategic Cooperation AgreementCeremonial Signing andFirst Anniversary Celebration

On November 7, 2023, during the 6th China International Import Expo, Omron and Medtronic held a strategic cooperation signing ceremony and the first anniversary celebration of their partnership. Following the signing of the strategic cooperation agreement at the 5th China International Import Expo in 2022, both parties have engaged in close and sincere collaboration in the field of atrial fibrillation and arrhythmia. In just one year, they have reached multiple cities to provide effective medical care for patients with atrial fibrillation and arrhythmia, jointly establishing a screening and treatment system for heart diseases and creating a new ecosystem for public cardiac health cooperation. This year, the two parties are embarking on a new starting point for cooperation and will expand their partnership into the field of hypertension, empowering innovative approaches and full-process value in hypertension diagnosis and treatment, bringing good news to more patients.

Omron

A global leader in healthcare and automation, with the brand vision of Going for ZERO – Preventive Healthcare, Making the World Healthier, and the goal of "Zero Cardiovascular and Cerebrovascular Events," dedicated to contributing to a healthy and comfortable life for every individual on Earth. Since entering the Chinese market in the 1990s, it has built strong brand recognition among consumers.

Medtronic

A Global Leader in Medical Technology, Committed to the Mission of "Alleviating Pain, Restoring Health, and Extending Life," Bringing Extraordinary Life Experiences to Patients Through Advanced Medical Technology, with Innovative Solutions Covering More Than 70 Key Disease Areas. As One of the First Multinational Medical Technology Enterprises to Enter China, Medtronic Has Introduced Over 500 Products to the Local Market, Demonstrating Its Commitment to Benefit Patients in China.

At this CIIE,Medtronic to Create 8 Major Thematic Exhibition Areas, Featuring Over 60 Innovative Exhibits，In the field of cardiology and vascular,The Upgraded World's Smallest Leadless Pacemaker, Micra^TMVR 2 and Micra^TM AV 2、PulseSelect^TMPulsed Field Ablation System, Symplicity Spyral^TMMulti-pole Radiofrequency Ablation System for Renal Artery Sympathetic Nerves Debuts for the First Time。

Omron will bring a series of innovative products in the cardiovascular field, expanding from daily blood pressure measurement to complication risk management and atrial fibrillation risk screening, to meet the needs of different consumers.Such asElectronic blood pressure monitors with atrial fibrillation detection prompts, electrocardiogram-integrated blood pressure monitors capable of simultaneously measuring blood pressure and performing ECG monitoring, innovative wristwatch-style blood pressure monitors with breakthrough designs, and nighttime wrist blood pressure monitors that effectively measure blood pressure while the user is asleep.

Both parties have once again leveraged the CIIE’s momentum to form a powerful alliance through innovative business models, playing to their respective strengths. They are committed to providing one-stop solutions for prevention, screening, diagnosis, treatment, and care in the fields of arrhythmia, atrial fibrillation, and hypertension. This collaboration aims to further expand the health cooperation ecosystem available to the public. Moving forward, they will continue to support the development of China's healthcare industry and contribute to the construction of "Healthy China"!

Building a New Ecosystem, Protecting "Heart" Health

Omron and Medtronic Celebrate One-Year Anniversary of Collaboration

Atrial fibrillation and arrhythmia are very common chronic diseases in China and high-risk factors that induce various cardiovascular diseases. Therefore, the prevention and treatment of cardiovascular and cerebrovascular diseases are not only related to personal health but also elevated to the strategic level of Healthy China.

Over the past year, Omron has closely collaborated with Medtronic and achieved results, successively conducting multiple patient education and free clinics in Nanjing, Jiangsu; Wuhan, Hubei; Guiyang, Guizhou; Urumqi, Xinjiang, and other places targeting patients with atrial fibrillation and arrhythmia. These efforts aim to accelerate therapy accessibility with excellent treatment capabilities and are dedicated to raising public awareness of cardiovascular health. Additionally,The two parties have also established pilot projects for atrial fibrillation screening and referral pathway construction in some provincial and municipal hospitals in China, scientifically standardizing the diagnosis and treatment of cardiovascular diseases, and building a healthy ecosystem for cardiovascular disease education, prevention, and treatment.

At the celebration ceremony,Mr. Zhao Yao, Director and General Manager of Omron Healthcare (China) Co., Ltd.Speech: "As two enterprises deeply engaged in the global healthcare field, Omron and Medtronic have been striving to serve every potential and existing cardiac patient within their respective areas of expertise by leveraging each other's strengths since the establishment of the strategic cooperation. We are working to educate people with 'three highs' (high blood pressure, high cholesterol, and high blood sugar) outside of hospitals about the preventability of atrial fibrillation. With innovative devices like the atrial fibrillation sphygmomanometer, we aim to help hypertensive patients detect atrial fibrillation risks early and ensure patients' well-being with Medtronic’s professional capabilities."

Mr. Lin Song, Vice President of Medtronic's Cardiac Rhythm, Cardiac Surgery, and Cardiac Ablation Business Teams in China, and Head of the Shared Functional Department for the Cardiovascular Business Portfolio in ChinaAlso mentioned in the speech: "The partnership between Medtronic and Omron is not only a strategic collaboration but also a fusion of mission and philosophy. In this cooperation, both parties think less about commercial development and more about patients' health and the future in the fields of arrhythmia, atrial fibrillation, and hypertension.Put Patient First——Patient First"The fundamental reason for two historically-established enterprises to come together lies in their shared commitment to cooperation and integration in technology, models, and even research and development fields, aiming to provide the best services and improve patients' lives."

Subsequently,Mr. Hua Chen, Vice President of Cardiac Rhythm Management Business at Medtronic China, Mr. Xinghai Zhang, Senior Director of Business Operations at Cardiac Ablation Solutions, Mr. Takashi Higashitani, Executive Deputy General Manager of Omron Healthcare (China) Co., Ltd., and Mr. Jingliang Liu, Deputy General ManagerTo mark the first anniversary of their cooperation, they delivered auspicious wishes on stage, jointly initiated the celebration ceremony, and continued to compose a promising "heart" rhythm for the future of the healthcare field!

(Photo: The attending guests include Mr. Zhao Yao, Mr. Donggu Longshi, Mr. Yuzhi Endo, Mr. Liu Jingliang, Ms. Jin Jiazheng, and Ms. Dong Meiqi from Omron; Mr. Lin Song, Mr. Chen Hua, Mr. Zhang Xinghai, Mr. Fu Cong, Ms. Ni Peizhi, and Mr. Zhang Peitao from Medtronic.)

Collaborative Blood Pressure Reduction, Healthy Future

Omron and Medtronic Further Establish Strategic Cooperation

Relevant report data shows that the number of adult hypertension patients in China has reached 245 million. Hypertension is one of the most common chronic diseases in China, with clinical challenges such as difficulty in accessing medical care and follow-up. It imposes a heavy disease burden on individual patients, families, and society. As a major public health issue, the prevention and treatment of hypertension cannot be delayed, and its treatment technologies and solutions are continuously being improved in practice.

Renal Artery Sympathetic Denervation (RDN) has opened a new paradigm in the clinical treatment of hypertension. With the evolution of relevant guidelines, it has been established as one of the "three key approaches" for blood pressure control. Medtronic has never ceased its exploration and breakthroughs in this technology, and currently,Medtronic's RDN technology has been launched in more than 60 countries and regions worldwide, benefiting over 25,000 patients. In China, thanks to the policies of the Boao Lecheng Medical Pilot Zone in Hainan, Medtronic has collaborated with several domestic cardiology experts to carry out the pilot application of RDN, allowing dozens of Chinese hypertension patients to benefit in advance from this innovative technology.

For a long time, Omron's various home health products, such as blood pressure monitors and blood glucose meters, have served numerous users, assisting in health monitoring and chronic disease management. To better address the challenges of chronic disease management, Omron actively collaborates with industry partners to explore solutions, jointly building an innovative management system that incorporates nighttime blood pressure monitors into the daily blood pressure monitoring of patients before and after RDN procedures.During the day, patients can complete blood pressure measurements through active monitoring; at night, patients can complete timed monitoring in their sleep by setting it in advance. Doctors can observe the changes in patients' blood pressure before and after surgery through multi-point blood pressure data measured throughout the day, and evaluate the treatment effect.

With the continuous innovation of medical technology, the emergence of innovative treatment solutions, and the empowerment of smart medical devices, the cooperation between Omron and Medtronic has broad space and prospects.Omron will leverage its advantages in channels such as communities and pharmacies, integrate Medtronic's product technologies and partner resources in the field of disease diagnosis and treatment, and carry out interdisciplinary academic exchanges. With cutting-edge medical technologies and intelligent healthcare products, they will jointly achieve continuous breakthroughs and innovations in the field of chronic disease management to benefit more patients and work together to outline a beautiful blueprint for a healthy life.

Mr. Yuhiko Endo, Vice President of Omron Healthcare (China) Co., Ltd.The speech stated: "As a global enterprise deeply engaged in the field of chronic diseases for many years, Omron is well aware of the vast number of patients with chronic diseases in China and the urgent medical needs. In the past, the treatment methods for hypertension mainly included lifestyle interventions and drug treatments. Now, pioneered by Medtronic, a new treatment method involving renal artery sympathetic denervation surgery has been developed. We are actively paying attention to this advancement and exploring new cooperative efforts. We believe that today's signing is a successful starting point. We look forward to collaborating with Medtronic to contribute to the cause of hypertension prevention and treatment, and to support the Healthy China 2030 goals."

Mr. Tao Jia, Vice President of Medtronic's Coronary and Renal Denervation Business Operations in ChinaMedtronic stated: "Committed to the mission of 'alleviating pain, restoring health, and extending life,' Medtronic is dedicated to driving therapy innovation through creativity and collaboration. Renal artery sympathetic radiofrequency ablation, as an effective complement to lifestyle improvements and medication, has broken the bottleneck in hypertension treatment. This collaboration marks an innovative journey jointly explored by Medtronic and Omron. Sharing a common vision, we leverage our respective strengths to provide patients with more comprehensive, convenient, and efficient health management solutions. Through technological innovation and upgraded management methods, we are fully committed to building a healthier and happier future."

Subsequently,Mr. Yushi Endo, Mr. Jia TaoOn stage, the signing ceremony was completed under the witness of the leaders from both sides.

(In the front row from left to right: Mr. Yoruyuki Endo from Omron, Mr. Jia Tao from Medtronic; in the back row from left to right: Ms. Meiqi Dong, Ms. Jiazheng Jin, Mr. Jingliang Liu, Mr. Takashi Higashitani, Mr. Yao Zhao from Omron; Mr. Song Lin, Ms. Tong Sun, Mr. Lingxiang Wu, Ms. Qin Wei, Mr. Peitao Zhang from Medtronic.)

Joining Forces to Lower Blood Pressure, Creating a Healthier Future Together. This strategic cooperation agreement marks a brand-new collaboration between Omron and Medtronic. Both parties will continue to deepen their strategic synergy, working hand in hand to explore a new ecosystem for comprehensive hypertension management medical services, providing patients with more safe, innovative, and efficient medical solutions. At the signing ceremony, both parties presented a scroll symbolizing a promising vision of cooperation. The scroll depicted the "one-stop blood pressure management" with Omron's blood pressure monitor and Medtronic’s RDN ablation catheter, showcasing the future vision of Omron and Medtronic jointly establishing a hypertension screening and treatment system and building an ecosystem for blood pressure management healthcare services.